Dr T.J Von Oertzen - Consultant Neurologist and Epileptologist (MD., F.R.C.P.)

Dr. von Oertzen studied medicine at Rheinische-Friedrich-Wilhelm University, Germany and completed his final year at University College of London in 1995. He was supervising consultant in Europe's largest centre for presurgical evaluation in epilepsy, Department of Epileptology, at the University of Bonn where he gained major experience in all aspects of blackouts, epilepsy, non epileptic attack disorders and other conditions. Dr. von Oertzen is fully trained in Neurophysiology, particularly in EEG (electroencephalogram recording of brainwaves) of both surface and intracranial recordings.

Dr. von Oertzen has been appointed as the lead clinician for the epilepsy service at the Atkinson Morley Neuroscience Centre, St George's Hospital, since 2004. At present, he is holding specialist clinics for first fits and blackouts, complex cases and people with drug refractory epilepsy including pre-surgical assessment. He holds an Honorary Senior Lecturer post at St George's University of London is also honorary Consultant Neurologist at Kingston Hospital.

Dr. von Oertzen has presented clinical and research data on national and international conferences. He has frequently published in medical journals and contributed to definite books about epilepsy. He is involved in raising awareness for epilepsy and providing continuous medical education for medical professionals.

Back to experts

Latest news

Clinical trials: how taking the pills can pay those bills.

April 20, 2022
The Guardian references Richmond Pharmacology in feature on reimbursement for clinical trial volunteers
Read more

Clinical trials and the patient perspective

May 6, 2022
Successful recruitment and retention of patients - an essential element to delivering clinical studies on time.
Read more

Events

The Future of Healthcare - March 2022

13:30 – 16:00, 22nd March 2022
Discover the intricacies of assessing abnormal liver functions in clinical trial volunteers and gain insights from the latest drug development trials using RNAi therapeutics.
View event